
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): 08/01/2012

Dynavax Technologies Corporation

(Exact name of registrant as specified in its charter)

Commission File Number: 001-34207

Delaware
(State or other jurisdiction of
incorporation)

33-0728374
(IRS Employer
Identification No.)

2929 Seventh Street, Suite 100
Berkeley, CA 94710-2753
(Address of principal executive offices, including zip code)

(510) 848-5100
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.02. Results of Operations and Financial Condition

On August 1, 2012, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the second quarter ended June 30, 2012. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

The information with respect to Item 2.02 in this current report and its accompanying exhibit shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this current report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Dynavax, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibit

Exhibit No. Description

99.1 Press Release, dated August 1, 2012 titled "Dynavax Reports Second Quarter 2012 Financial Results."

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dynavax Technologies Corporation

Date: August 01, 2012

By: /s/ Jennifer Lew

Jennifer Lew
Vice President, Finance

EXHIBIT INDEX

Exhibit No.	Description
EX-99.1	Press Release, dated August 1, 2012, "Dynavax Reports Second Quarter 2012 Financial Results."

Contacts:

Jennifer Lew
Vice President, Finance

510-665-7217
jlew@dynavax.com

Michael Ostrach
Vice President and Chief Business
Officer

510-665-7257
mostrach@dynavax.com

DYNAVAX REPORTS SECOND QUARTER 2012 FINANCIAL RESULTS

BERKELEY, CA - August 1, 2012 - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2012. The Company had \$160.2 million in cash, cash equivalents and marketable securities as of June 30, 2012 as compared to \$114.0 million at December 31, 2011. Total cash for the second quarter of 2012 included \$69.6 million in net proceeds from the sale of 17,500,000 shares of common stock.

Total revenues were \$2.7 million and \$5.0 million for the three and six months ended June 30, 2012, respectively, compared to \$7.3 million and \$9.0 million, respectively, reported for the same periods of 2011. Revenues for the second quarter and first half of 2011 included a \$6 million milestone earned under the Company's collaboration with GlaxoSmithKline.

Research and development expenses were \$11.4 million and \$23.8 million for the three and six months ended June 30, 2012, respectively. This compared to \$13.3 million and \$27.9 million, respectively, reported for the same periods of 2011. Research and development expenses decreased primarily due to the significant decline in clinical activities for HEPLISAV™.

General and administrative expenses were \$6.0 million and \$11.8 million for the second quarter and first half of 2012, respectively, compared to \$4.1 million and \$8.8 million, respectively, in the same periods of the prior year. General and administrative expenses increased primarily due to growth in commercial development expenses.

About HEPLISAV

HEPLISAV is an investigational adult hepatitis B vaccine for which a U.S. BLA has been accepted for review by the FDA and a Marketing Authorization Application (MAA) has been submitted. In Phase 3 trials, HEPLISAV demonstrated higher and earlier protection with fewer doses than currently licensed vaccines. Dynavax has worldwide commercial rights to HEPLISAV. HEPLISAV combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist known to enhance the immune response.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide rapid and earlier protection with fewer doses than currently licensed vaccines. For more information visit www.dynavax.com.

- tables to follow -

**DYNAVAX TECHNOLOGIES CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)**

(Unaudited)

	Three Months Ended		Six Months Ended	
	<u>June 30,</u>		<u>June 30,</u>	
	<u>2012</u>	<u>2011</u>	<u>2012</u>	<u>2011</u>

Revenues:

Collaboration revenue	\$ 1,623	\$ 6,363	\$ 2,552	\$ 6,729
Grant revenue	882	890	1,969	1,779

Service and license revenue	<u>179</u>	<u>16</u>	<u>513</u>	<u>505</u>
Total revenues	2,684	7,269	5,034	9,013
Operating expenses:				
Research and development	11,376	13,257	23,781	27,929
General and administrative	5,957	4,054	11,750	8,808
Amortization of intangible assets	=	<u>54</u>	=	<u>299</u>
Total operating expenses	<u>17,333</u>	<u>17,365</u>	<u>35,531</u>	<u>37,036</u>
Loss from operations	(14,649)	(10,096)	(30,497)	(28,023)
Interest income	65	23	117	56
Interest expense	(589)	(487)	(1,176)	(977)
Other income (expense)	<u>63</u>	<u>(75)</u>	<u>(59)</u>	<u>(157)</u>
Net loss	<u>\$(15,110)</u>	<u>\$(10,635)</u>	<u>\$(31,615)</u>	<u>\$(29,101)</u>
Basic and diluted net loss per share	<u>\$(0.09)</u>	<u>\$(0.09)</u>	<u>\$(0.20)</u>	<u>\$(0.25)</u>
Shares used to compute basic and diluted net loss per share	<u>167,697</u>	<u>117,864</u>	<u>161,564</u>	<u>116,801</u>

DYNAVAX TECHNOLOGIES CORPORATION

SELECTED BALANCE SHEET DATA

(In thousands)

(Unaudited)

	June 30,	December 31,
	<u>2012</u>	<u>2011</u>
Assets		
Cash and cash equivalents and marketable securities	\$ 160,199	\$ 113,961
Property and equipment, net	6,833	6,163
Goodwill	2,356	2,312
Other assets	<u>6,507</u>	<u>11,666</u>
Total assets	<u>\$ 175,895</u>	<u>\$ 134,102</u>
Liabilities and stockholders' equity		
Accounts payable	\$ 1,155	\$ 2,040

Accrued liabilities	1,950	8,170
Current portion of deferred revenue	2,859	4,210
Non-current portion of deferred revenue	5,312	6,386
Short-term note payable to Holdings	13,905	12,810
Stockholders' equity	<u>144,708</u>	<u>99,880</u>
Total liabilities and stockholders' equity	<u>\$ 175,895</u>	<u>\$ 134,102</u>
	###	